Rapid health technology assessment of 4 kinds of drugs for membranous nephropathy
- VernacularTitle:4种膜性肾病治疗药物的快速卫生技术评估
- Author:
Shengyu ZHANG
1
,
2
;
Laixinyue SHU
3
;
Pengli ZHU
1
,
2
;
Lijuan NING
1
,
2
;
Yongwu CHEN
1
,
2
;
Fei WU
1
,
2
;
Yingqi WU
1
,
2
;
Aizong SHEN
1
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of USTC （Anhui Provincial Hospital），Hefei 230001，China
2. Anhui Pharmaceutical Clinical Comprehensive Evaluation Technology Center，Hefei 230001，China
3. School of Pharmacy，Anhui University of Chinese Medicine，Hefei 230013，China
- Publication Type:Journal Article
- Keywords:
rapid health technology assessment;
membranous nephropathy;
cyclosporine A;
tacrolimus;
cyclophosphamide
- From:
China Pharmacy
2023;34(8):988-992
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To compare the efficacy， safety and economy of tacrolimus （TAC）， cyclosporin A （CsA）， cyclophosphamide （CTX） and rituximab （RTX） in the treatment of membranous nephropathy （MN）. METHODS Retrieved from Pubmed， the Cochrane Library， Wanfang data， CNKI and health technology assessment （HTA） official website， HTA reports， systematic reviews/meta-analysis and pharmacoeconomic studies about TAC， CsA， CTX and RTX combined with glucocorticoid in the treatment of MN were collected during the inception and Mar. 2022. After data extraction and quality evaluation， descriptive analysis was performed on the results of the included studies. RESULTS A total of 15 articles were included， involving 13 systematic reviews/meta-analysis and 2 pharmacoeconomic studies. In terms of efficacy， TAC and CsA showed significant advantages in increasing the response rate， and could improve the levels of urine protein， serum albumin， serum creatinine and serum total cholesterol. In terms of safety， the incidence of adverse reaction induced by TAC， CsA and RTX was low and the symptoms were mild. In terms of economics， CTX cost lower but caused severe adverse reaction； TAC cost higher but showed higher remission rate and good safety. CONCLUSIONS TAC combined with glucocorticoid may be the recommended scheme for MN.
